Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban

Document Type : Abstracts

Abstract

No enough information available in matter of
patient on Rivaroxaban a direct factor Xa
inhibitor specially in Saudi population. In
addition, patient with chronic kidney disease,
valvular atrial fibrillation or liver disease must
not be considered for such therapeutic change.
This study will be the first to give an idea about
current practice being used at anticoagulant
clinic and criteria used to choose patients were
switched to Rivaroxaban

Files

Share

How to cite

Statistics